REGENERON PHARMACEUTICALS, INC.(REGN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #138 of 2,879 stocksTOP 5%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
REGN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for REGENERON PHARMACEUTICALS, INC. (REGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores REGN at 75.1/100 on a 32-signal composite quality model, placing it at rank #138 of 2,879 stocks — the top 5% of the AI-ranked universe. REGN scores in the top quartile across revenue scale (89.9), profitability (89.8), balance sheet strength (88.2). Shareholder dilution risk is elevated at 21.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), REGENERON PHARMACEUTICALS, INC. reports quarterly revenue of $3.6B, net income of $727.2M, an operating margin of 17.8%. Top institutional holders of REGN by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. REGN trades on the Nasdaq exchange and files with the SEC under CIK 872589. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate REGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REGENERON PHARMACEUTICALS, INC. directly from SEC EDGAR. REGENERON PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 8 and 89 since 2021, currently 75.1 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.
What's Driving REGN's Business? Latest 10-Q Breakdown
AI-extracted from REGENERON PHARMACEUTICALS, INC.'s 10-Q filed 2026-04-29 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q1 revenue grew 19% YoY to $3.6B, driven by 33% growth in Dupixent profits and 77% growth in EYLEA HD sales, but EYLEA declined 40% as biosimilar competition pressures the franchise.
Biggest Revenue Drivers
Total revenue: $3.6B+19% YoY
Regeneron's share of Dupixent and Kevzara profits increased primarily due to higher Dupixent sales, partially offset by development expense reimbursements to Sanofi.
EYLEA HD sales grew 52% YoY on higher volumes, while total EYLEA declined 12% due to continued biosimilar competition and patient transition to EYLEA HD.
Regeneron's share of EYLEA profits outside the US declined due to lower EYLEA sales outside the United States.
Largest Expense Items
Higher spending on direct R&D programs including Lynozyfic, Ordspono, and Factor XI inhibitors; increased clinical manufacturing and indirect costs.
Increased commercialization-related expenses for EYLEA HD and Libtayo, plus higher headcount-related costs, partially offset by lower charitable contributions.
Gross margin declined to 76% from 81% due to unabsorbed manufacturing costs and inventory write-offs from temporary Limerick, Ireland facility production interruption.
Higher costs in connection with manufacturing drug supplies for Sanofi and Bayer collaborations and others.
Margins: Gross margin on net product sales declined to 76% from 81% YoY, primarily due to unabsorbed manufacturing costs and higher inventory write-offs from a temporary production interruption at the Limerick, Ireland facility during Q1 2026. The company expects margin pressure to continue until production returns to normal levels by end of Q2 2026.
Watch Items from the Filing
- EYLEA franchise under severe biosimilar pressure: EYLEA net sales declined 36% in Q1 2026 vs Q1 2025 due to FDA-approved biosimilar competition launched in 2024-2025; additional biosimilar launches expected H2 2026. EYLEA HD growth insufficient to fully offset declines.
- Customer concentration: Two distributor customers represent 75% of gross product revenue. Loss of either distributor would materially harm results of operations.
- Manufacturing interruption impact ongoing: Limerick, Ireland facility production interrupted in Q1 2026 due to unanticipated facility repairs; resumed in Q2 2026 but gross margin will remain pressured until production normalizes by end of Q2 2026.
- U.S. Government Agreements (April 2026) commit to Most-Favored-Nation pricing for Medicaid and certain future medicines, free provision of Otarmeni gene therapy, and participation in TrumpRx.gov direct purchasing platform; no tariffs through January 2029 if manufacturing/R&D investment commitments maintained. Long-term margin impact uncertain.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q1 2026
$3.6B
Net Income
Q1 2026
$727.2M
Free Cash Flow
Q1 2026
$848.3M
Operating Margin
Q1 2026
17.8%
D/E Ratio
Q1 2026
0.06
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+7.8% YoYNet Income
-8.9% YoYOperating Income
-14.6% YoYEPS (Diluted)
-9.0% YoYTotal Assets
+13.2% YoYTotal Debt
+0.1% YoYOp. Cash Flow
-8.4% YoY| Metric | FY 2023 | FY 2022 | FY 2019 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|
| Revenue | $13.12B +7.8% | $12.17B +85.6% | $6.56B +11.7% | $5.87B +20.8% | $4.86B +18.4% | $4.10B |
| Net Income | $3.95B -8.9% | $4.34B +105.0% | $2.12B +76.5% | $1.20B +33.8% | $895.5M +40.8% | $636.1M |
| Operating Income | $4.05B -14.6% | $4.74B +114.4% | $2.21B +6.3% | $2.08B +56.3% | $1.33B +6.3% | $1.25B |
| EPS (Diluted) | $34.77 -9.0% | $38.22 +107.0% | $18.46 +78.5% | $10.34 +34.3% | $7.70 +39.5% | $5.52 |
| Total Assets | $33.08B +13.2% | $29.21B +97.3% | $14.81B +68.9% | $8.76B +25.7% | $6.97B +24.3% | $5.61B |
| Total Debt | $1.98B +0.1% | $1.98B | $0.00 | — | — | — |
| Operating Cash Flow | $4.59B -8.4% | $5.01B +106.4% | $2.43B +85.9% | $1.31B -12.0% | $1.49B +11.7% | $1.33B |
AI Insight: REGN Ratio Trends
REGN profitability metrics have collapsed across the board—operating margin down 620bp, ROIC down 320bp—with Q1 2026 showing the steepest declines.
• Operating margin deteriorated from 31.7% in Q3 2024 to 17.8% in Q1 2026, a 390bp decline over six quarters.
• ROIC contracted from 15.1% in Q3 2024 to 7.7% in Q1 2026; Q1 2026 marks the lowest return on invested capital in the dataset.
• Net profit margin fell to 20.2% in Q1 2026 from 40.4% in Q2 2024, a 20pp decline indicating severe earnings pressure.
⚠ Q1 2026 shows consistent weakness across ROE (9.3%), ROA (7.1%), and ROIC (7.7%)—all near multi-quarter lows.
⚠ Leverage stable at 0.06 D/E, but deteriorating profitability suggests underlying operational challenges unrelated to capital structure.
Get alerted when REGN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for REGENERON PHARMACEUTICALS, INC. including:
Top Institutional Holders of REGN
BlackRock, Inc.
$6.9B8,947,735 shVANGUARD CAPITAL MANAGEMENT LLC
$5.1B6,654,913 shSTATE STREET CORP
$3.6B4,664,478 shDODGE & COX
$3.4B4,458,238 shFRANKLIN RESOURCES INC
$2.1B2,722,071 shGEODE CAPITAL MANAGEMENT, LLC
$2.0B2,607,732 shNuveen, LLC
$1.6B2,065,064 shLOOMIS SAYLES & CO L P
$1.5B1,912,310 shWELLINGTON MANAGEMENT GROUP LLP
$1.4B1,837,459 shInvesco Ltd.
$1.3B1,724,478 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $6.9B | 8,947,735 |
| VANGUARD CAPITAL MANAGEMENT LLC | $5.1B | 6,654,913 |
| STATE STREET CORP | $3.6B | 4,664,478 |
| DODGE & COX | $3.4B | 4,458,238 |
| FRANKLIN RESOURCES INC | $2.1B | 2,722,071 |
| GEODE CAPITAL MANAGEMENT, LLC | $2.0B | 2,607,732 |
| Nuveen, LLC | $1.6B | 2,065,064 |
| LOOMIS SAYLES & CO L P | $1.5B | 1,912,310 |
| WELLINGTON MANAGEMENT GROUP LLP | $1.4B | 1,837,459 |
| Invesco Ltd. | $1.3B | 1,724,478 |
More Healthcare Companies
View all Healthcare →Put REGN on your watchlist
Track score changes the day REGENERON PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is REGN a good stock to buy?
13F Pro's AI-powered analysis of REGENERON PHARMACEUTICALS, INC. (REGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for REGN are available on the REGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own REGN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling REGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of REGENERON PHARMACEUTICALS, INC.'s investment landscape.